Literature DB >> 26380023

Up-regulation of HDAC9 promotes cell proliferation through suppressing p53 transcription in osteosarcoma.

Yu-Xin Zhao1, Yi-Sheng Wang2, Qi-Qing Cai3, Jia-Qiang Wang3, Wei-Tao Yao3.   

Abstract

Increasing studies have demonstrated that altered expression of histone deacetylases (HDACs) plays a critical role in the tumorigenesis through up-regulation or down-regulation of key genes involved in cell proliferation, cell-cycle regulation and apoptosis. In the present study, the expression and function of HDAC9 were investigated in osteosarcoma. Quantitative real-time PCR and Western blot analysis found that HDAC9 was up-regulated in osteosarcoma tissues, when compared with that in adjacent normal tissues. In vitro studies further demonstrated that overexpression of HDAC9 in U2OS and MG63 cells promoted cell proliferation and invasion. Using chromatin immunoprecipitation (ChIP) assay, we found that HDAC9 epigenetically repressed p53 transcription through binding to its proximal promoter region. Therefore, our data suggest an important role for HDAC9/p53 regulatory pathway in the osteosarcoma progression.

Entities:  

Keywords:  HDAC9; Osteosarcoma; cell proliferation; epigenetics; p53

Year:  2015        PMID: 26380023      PMCID: PMC4565406     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  24 in total

Review 1.  Histone deacetylases as targets for treatment of multiple diseases.

Authors:  Jinhua Tang; Haidong Yan; Shougang Zhuang
Journal:  Clin Sci (Lond)       Date:  2013-06       Impact factor: 6.124

Review 2.  Review of the molecular pathogenesis of osteosarcoma.

Authors:  Jin-Peng He; Yun Hao; Xiao-Lin Wang; Xiao-Jin Yang; Jing-Fan Shao; Feng-Jin Guo; Jie-Xiong Feng
Journal:  Asian Pac J Cancer Prev       Date:  2014

Review 3.  New and emerging HDAC inhibitors for cancer treatment.

Authors:  Alison C West; Ricky W Johnstone
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

Review 4.  Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials.

Authors:  Tianzhu Qiu; Li Zhou; Wei Zhu; Tongshan Wang; Jian Wang; Yongqian Shu; Ping Liu
Journal:  Future Oncol       Date:  2013-02       Impact factor: 3.404

Review 5.  HDAC inhibition and graft versus host disease.

Authors:  Sung Choi; Pavan Reddy
Journal:  Mol Med       Date:  2011-01-08       Impact factor: 6.354

Review 6.  Mammalian DNA repair: HATs and HDACs make their mark through histone acetylation.

Authors:  Fade Gong; Kyle M Miller
Journal:  Mutat Res       Date:  2013-08-06       Impact factor: 2.433

Review 7.  Translational biology of osteosarcoma.

Authors:  Maya Kansara; Michele W Teng; Mark J Smyth; David M Thomas
Journal:  Nat Rev Cancer       Date:  2014-10-16       Impact factor: 60.716

Review 8.  Histone lysine demethylases as targets for anticancer therapy.

Authors:  Jonas W Højfeldt; Karl Agger; Kristian Helin
Journal:  Nat Rev Drug Discov       Date:  2013-11-15       Impact factor: 84.694

9.  HDAC6 promotes hepatocellular carcinoma progression by inhibiting P53 transcriptional activity.

Authors:  Gang Ding; He-Dai Liu; Qian Huang; Hong-Xiang Liang; Zhao-Han Ding; Zhi-Jun Liao; Gang Huang
Journal:  FEBS Lett       Date:  2013-02-10       Impact factor: 4.124

Review 10.  Pre-clinical studies of epigenetic therapies targeting histone modifiers in lung cancer.

Authors:  Kenneth Huffman; Elisabeth D Martinez
Journal:  Front Oncol       Date:  2013-09-09       Impact factor: 6.244

View more
  9 in total

1.  HDAC9 overexpression confers invasive and angiogenic potential to triple negative breast cancer cells via modulating microRNA-206.

Authors:  Eric Salgado; Xuehai Bian; Amber Feng; Hyunsuk Shim; Zhongxing Liang
Journal:  Biochem Biophys Res Commun       Date:  2018-06-23       Impact factor: 3.575

2.  Deregulated expression of HDAC9 in B cells promotes development of lymphoproliferative disease and lymphoma in mice.

Authors:  Veronica S Gil; Govind Bhagat; Louise Howell; Jiyuan Zhang; Chae H Kim; Sven Stengel; Francisco Vega; Arthur Zelent; Kevin Petrie
Journal:  Dis Model Mech       Date:  2016-10-28       Impact factor: 5.758

3.  Downregulation of p53 drives autophagy during human trophoblast differentiation.

Authors:  Martin Gauster; Sabine Maninger; Monika Siwetz; Alexander Deutsch; Amin El-Heliebi; Dagmar Kolb-Lenz; Ursula Hiden; Gernot Desoye; Florian Herse; Andreas Prokesch
Journal:  Cell Mol Life Sci       Date:  2017-10-27       Impact factor: 9.261

4.  Vitamin D-Related Genes, Blood Vitamin D Levels and Colorectal Cancer Risk in Western European Populations.

Authors:  Veronika Fedirko; Hannah B Mandle; Wanzhe Zhu; David J Hughes; Afshan Siddiq; Pietro Ferrari; Isabelle Romieu; Elio Riboli; Bas Bueno-de-Mesquita; Fränzel J B van Duijnhoven; Peter D Siersema; Anne Tjønneland; Anja Olsen; Vittorio Perduca; Franck Carbonnel; Marie-Christine Boutron-Ruault; Tilman Kühn; Theron Johnson; Aleksandrova Krasimira; Antonia Trichopoulou; Periklis Makrythanasis; Dimitris Thanos; Salvatore Panico; Vittorio Krogh; Carlotta Sacerdote; Guri Skeie; Elisabete Weiderpass; Sandra Colorado-Yohar; Núria Sala; Aurelio Barricarte; Maria-Jose Sanchez; Ramón Quirós; Pilar Amiano; Björn Gylling; Sophia Harlid; Aurora Perez-Cornago; Alicia K Heath; Konstantinos K Tsilidis; Dagfinn Aune; Heinz Freisling; Neil Murphy; Marc J Gunter; Mazda Jenab
Journal:  Nutrients       Date:  2019-08-20       Impact factor: 6.706

5.  Mechanism and Molecular Network of RBM8A-Mediated Regulation of Oxaliplatin Resistance in Hepatocellular Carcinoma.

Authors:  Rong Liang; Jinyan Zhang; Zhihui Liu; Ziyu Liu; Qian Li; Xiaoling Luo; Yongqiang Li; Jiazhou Ye; Yan Lin
Journal:  Front Oncol       Date:  2021-01-22       Impact factor: 6.244

6.  MicroRNA-30c-regulated HDAC9 mediates chemoresistance of breast cancer.

Authors:  Zhongxing Liang; Amber Feng; Hyunsuk Shim
Journal:  Cancer Chemother Pharmacol       Date:  2020-01-06       Impact factor: 3.288

7.  MicroRNA-101-3p inhibits proliferation in retinoblastoma cells by targeting EZH2 and HDAC9.

Authors:  Qifang Jin; Wenfeng He; Leifeng Chen; Yang Yang; Ke Shi; Zhipeng You
Journal:  Exp Ther Med       Date:  2018-07-04       Impact factor: 2.447

8.  miR‑181b‑p53 negative feedback axis regulates osteosarcoma cell proliferation and invasion.

Authors:  Jun Wan; Feng Long; Can Zhang; Yupeng Liu
Journal:  Int J Mol Med       Date:  2020-03-31       Impact factor: 4.101

Review 9.  Histone deacetylase (HDAC) 9: versatile biological functions and emerging roles in human cancer.

Authors:  Chun Yang; Stéphane Croteau; Pierre Hardy
Journal:  Cell Oncol (Dordr)       Date:  2021-07-27       Impact factor: 7.051

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.